Exome Asset Management
Latest statistics and disclosures from Exome Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are IONS, CYTK, BBIO, COGT, GH, and represent 21.69% of Exome Asset Management's stock portfolio.
- Added to shares of these 10 stocks: IMAB (+$5.4M), APGE, ARWR, CVS, UTHR, PPH, IMVT, LLY, CTMX, VERA.
- Started 30 new stock positions in APGE, Praxis Precision Medicines I, Centessa Pharmaceuticals, Karyopharm Therapeutics, GKOS, ATYR, Mbx Biosciences, ORIC, ALMS, Mbx Biosciences.
- Reduced shares in these 10 stocks: Ishares Tr Index option (-$7.4M), FULC, SRRK, SNDX, VSTM, GERN, Nektar Therapeutics, CNTA, DYN, RGNX.
- Sold out of its positions in Altimmune, ANAB, APLS, BCRX, CLDX, CMPS, CRNX, DYN, ELDN, ELEV.
- Exome Asset Management was a net buyer of stock by $6.8M.
- Exome Asset Management has $165M in assets under management (AUM), dropping by 22.78%.
- Central Index Key (CIK): 0002011932
Tip: Access up to 7 years of quarterly data
Positions held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Exome Asset Management
Exome Asset Management holds 68 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals (IONS) | 5.2 | $8.6M | +8% | 131k | 65.42 |
|
| Cytokinetics Com New (CYTK) | 4.7 | $7.8M | +22% | 142k | 54.96 |
|
| Bridgebio Pharma (BBIO) | 4.2 | $6.9M | -14% | 133k | 51.94 |
|
| Cogent Biosciences (COGT) | 3.9 | $6.4M | -16% | 444k | 14.36 |
|
| Guardant Health (GH) | 3.7 | $6.1M | 98k | 62.48 |
|
|
| Eli Lilly & Co. (LLY) | 3.6 | $6.0M | +68% | 7.9k | 763.00 |
|
| I Mab Sponsored Ads (IMAB) | 3.3 | $5.4M | NEW | 1.4M | 3.78 |
|
| Praxis Precision Medicines I Com New (PRAX) | 3.3 | $5.4M | +72% | 102k | 53.00 |
|
| Vera Therapeutics Cl A (VERA) | 2.7 | $4.5M | +103% | 156k | 29.06 |
|
| Astrazeneca Sponsored Adr (AZN) | 2.6 | $4.3M | 28k | 150.54 |
|
|
| Disc Medicine (IRON) | 2.5 | $4.1M | 61k | 66.08 |
|
|
| 89bio (ETNB) | 2.4 | $4.0M | +17% | 274k | 14.70 |
|
| Apogee Therapeutics (APGE) | 2.3 | $3.8M | NEW | 94k | 39.73 |
|
| Travere Therapeutics (TVTX) | 2.3 | $3.8M | +2% | 157k | 23.90 |
|
| Tenet Healthcare Corp Com New (THC) | 2.2 | $3.7M | -32% | 18k | 203.04 |
|
| Arrowhead Pharmaceuticals (ARWR) | 2.2 | $3.6M | NEW | 105k | 34.49 |
|
| CVS Caremark Corporation (CVS) | 2.0 | $3.3M | NEW | 44k | 75.39 |
|
| Soleno Therapeutics (SLNO) | 2.0 | $3.3M | +16% | 48k | 67.60 |
|
| Natera (NTRA) | 1.8 | $3.0M | 19k | 160.97 |
|
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.8 | $2.9M | -17% | 230k | 12.65 |
|
| Intuitive Surgical Com New (ISRG) | 1.7 | $2.8M | 6.4k | 447.23 |
|
|
| Edgewise Therapeutics (EWTX) | 1.7 | $2.8M | +39% | 173k | 16.22 |
|
| United Therapeutics Corporation (UTHR) | 1.7 | $2.8M | NEW | 6.6k | 419.21 |
|
| Akero Therapeutics (AKRO) | 1.7 | $2.8M | 59k | 47.48 |
|
|
| Vaneck Etf Trust Pharmaceutcl Etf Call Option (PPH) | 1.6 | $2.7M | NEW | 30k | 90.36 |
|
| Travere Therapeutics Call Call Option | 1.6 | $2.6M | 110k | 23.90 |
|
|
| Immunovant (IMVT) | 1.5 | $2.6M | NEW | 159k | 16.12 |
|
| Geron Corporation (GERN) | 1.5 | $2.5M | -45% | 1.9M | 1.37 |
|
| Cytomx Therapeutics (CTMX) | 1.4 | $2.4M | NEW | 745k | 3.19 |
|
| Penumbra (PEN) | 1.4 | $2.3M | 9.0k | 253.32 |
|
|
| Glaukos (GKOS) | 1.3 | $2.2M | NEW | 27k | 81.55 |
|
| Liquidia Corporation Com New (LQDA) | 1.3 | $2.1M | +359% | 94k | 22.74 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.3 | $2.1M | -47% | 88k | 24.25 |
|
| Novo-nordisk A S Call Call Option | 1.2 | $1.9M | NEW | 35k | 55.49 |
|
| 10x Genomics Cl A Com (TXG) | 1.2 | $1.9M | 164k | 11.69 |
|
|
| AmerisourceBergen (COR) | 1.1 | $1.9M | 6.0k | 312.53 |
|
|
| Syndax Pharmaceuticals (SNDX) | 1.1 | $1.8M | -61% | 118k | 15.38 |
|
| Waystar Holding Corp (WAY) | 1.1 | $1.8M | 47k | 37.92 |
|
|
| Sarepta Therapeutics Note 1.250% 9/1 | 1.1 | $1.8M | 2.0M | 0.88 |
|
|
| Karyopharm Therapeutics Note 3.000%10/1 | 1.0 | $1.6M | 2.0M | 0.82 |
|
|
| Universal Hlth Svcs CL B (UHS) | 1.0 | $1.6M | -21% | 8.0k | 204.44 |
|
| Oric Pharmaceuticals (ORIC) | 0.9 | $1.4M | NEW | 121k | 12.00 |
|
| Procept Biorobotics Corp (PRCT) | 0.9 | $1.4M | NEW | 40k | 35.69 |
|
| Inspire Med Sys (INSP) | 0.8 | $1.4M | NEW | 19k | 74.20 |
|
| Uniqure Nv SHS (QURE) | 0.8 | $1.3M | NEW | 22k | 58.37 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.8 | $1.3M | NEW | 178k | 7.17 |
|
| Avalo Therapeutics Com New (AVTX) | 0.8 | $1.3M | NEW | 100k | 12.71 |
|
| Liquidia Corporation Put Put Option | 0.7 | $1.2M | NEW | 53k | 22.74 |
|
| Gossamer Bio (GOSS) | 0.7 | $1.2M | -58% | 452k | 2.63 |
|
| Alumis (ALMS) | 0.7 | $1.2M | NEW | 293k | 3.99 |
|
| Upstream Bio (UPB) | 0.6 | $977k | NEW | 52k | 18.81 |
|
| Arcturus Therapeutics Hldgs Put Put Option | 0.6 | $922k | NEW | 50k | 18.43 |
|
| Mbx Biosciences (MBX) | 0.6 | $917k | -16% | 52k | 17.50 |
|
| Fulcrum Therapeutics (FULC) | 0.6 | $909k | -77% | 99k | 9.20 |
|
| Mbx Biosciences Put Put Option | 0.5 | $884k | NEW | 51k | 17.50 |
|
| Cogent Biosciences Call Call Option | 0.4 | $646k | NEW | 45k | 14.36 |
|
| Centessa Pharmaceuticals Put Put Option | 0.4 | $606k | NEW | 25k | 24.25 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.3 | $537k | 13k | 40.99 |
|
|
| Praxis Precision Medicines I Call Call Option | 0.3 | $530k | NEW | 10k | 53.00 |
|
| Mbx Biosciences Call Call Option | 0.3 | $525k | NEW | 30k | 17.50 |
|
| ACADIA Pharmaceuticals Put Option (ACAD) | 0.3 | $427k | -78% | 20k | 21.34 |
|
| Arbutus Biopharma (ABUS) | 0.2 | $343k | 76k | 4.54 |
|
|
| Precigen Put Put Option | 0.2 | $329k | NEW | 100k | 3.29 |
|
| Karyopharm Therapeutics Put Put Option | 0.2 | $315k | NEW | 48k | 6.54 |
|
| Replimune Group (REPL) | 0.2 | $308k | -81% | 74k | 4.19 |
|
| Ventyx Biosciences (VTYX) | 0.1 | $189k | NEW | 61k | 3.11 |
|
| Immunic (IMUX) | 0.1 | $153k | NEW | 174k | 0.88 |
|
| Atyr Pharma Com New Call Option (ATYR) | 0.0 | $29k | NEW | 40k | 0.72 |
|
Past Filings by Exome Asset Management
SEC 13F filings are viewable for Exome Asset Management going back to 2023
- Exome Asset Management 2025 Q3 filed Nov. 14, 2025
- Exome Asset Management 2025 Q2 restated filed Aug. 15, 2025
- Exome Asset Management 2025 Q1 restated filed May 16, 2025
- Exome Asset Management 2025 Q1 filed May 15, 2025
- Exome Asset Management 2024 Q4 filed Feb. 14, 2025
- Exome Asset Management 2024 Q3 amended filed Dec. 13, 2024
- Exome Asset Management 2024 Q2 restated filed Oct. 3, 2024
- Exome Asset Management 2024 Q2 filed Aug. 14, 2024
- Exome Asset Management 2024 Q1 filed May 15, 2024
- Exome Asset Management 2023 Q4 filed Feb. 15, 2024